Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis

Journal of Personalized Medicine

MaríaCarmen Ramírez Tortosa¹  MaríaJosé Zarzuelo Romero²  MiguelÁngel Calleja Hernández³  Cristina Pérez Ramírez³  MaríaIsabel Carrasco Campos⁴  Alberto Jiménez Morales⁴  Almudena Sánchez Martín⁴ 

[1] Department of Biochemistry, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain;Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain;Pharmacogenetics Unit, Pharmacy Service, Virgen Macarena University Hospital, 41009 Seville, Spain;Pharmacogenetics Unit, Pharmacy Service, Virgen de las Nieves University Hospital, 18014 Granada, Spain;

关键词: multiple sclerosis;    natalizumab;    fingolimod;    teriflunomide;    dimethyl fumarate;    alemtuzumab;   

DOI  :  10.3390/jpm11050335

来源: DOAJ

【 摘 要 】

The introduction of new therapies for the treatment of multiple sclerosis (MS) is a very recent phenomenon and little is known of their mechanism of action. Moreover, the response is subject to interindividual variability and may be affected by genetic factors, such as polymorphisms in the genes implicated in the pathologic environment, pharmacodynamics, and metabolism of the disease or in the mechanism of action of the medications, influencing the effectiveness of these therapies. This review evaluates the impact of pharmacogenetics on the response to treatment with new therapies in patients diagnosed with MS. The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients. However, there are few existing studies and their samples are small, making it difficult to generalize the role of these genes in treatment with new therapies. Studies with larger sample sizes and longer follow-up are therefore needed to confirm the results of these studies.

【 授权许可】

Unknown